• Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Akebia Therapeutics Inc

+ Add to Watchlist

AX9:GR

16.645 EUR 0.880 5.02%

As of 02:11:20 ET on 08/22/2014.

Snapshot for Akebia Therapeutics Inc (AX9)

Open: 16.650 Day's Range: 16.645 - 16.655 Volume: 0
Previous Close: 17.525 52wk Range: 12.320 - 21.360 1-Yr Rtn: -

Stock Chart for AX9

No chart data available.
  • AX9:GR 16.650
  • 1D
  • 1M
  • 1Y
17.525
Interactive AX9 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AX9

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -4.5600
Est. PEG Ratio -
Market Cap (M EUR) 337.28
Shares Outstanding (M) 20.26
30 Day Average Volume 0
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/20/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AX9

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AX9

Akebia Therapeutics, Inc. manufactures biopharmaceutical products. The Company develop and distributes novel therapeutics based on the biology of hypoxia inducible factor (HIF) for patients with kidney diseases. Akebia Therapeutics serves customers in the United States.

Jason A AmelloSenior VP/CFO/TreasurerJohn P ButlerPresident/CEO
Brad MaroniSenior VP/Chief Medical OfficerNicole R Hadas "Nikki"VP/General Counsel
More Company Profile & Key Executives for AX9

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil